Literature DB >> 9516926

Reduced expression of interleukin 6 in undifferentiated thyroid carcinoma: in vitro and in vivo studies.

F Basolo1, L Fiore, L Pollina, G Fontanini, P G Conaldi, A Toniolo.   

Abstract

Cytokines appear to play an important role in the development and progression of epithelial tumors. Cultured normal human thyroid follicular cells constitutively release high levels of interleukin-6 (IL-6) and IL-8, together with low to moderate levels of transforming growth factor-alpha (TGF-alpha) and TGF-beta. IL-6 appears to play multiple functions in thyroid physiology and disease. Because certain data indicate an inverse relationship between IL-6 production and epithelial tumor aggressiveness, we used both tissue culture methods and histochemical techniques to search for possible alterations of cytokine expression in thyroid carcinomas. As compared to cultures from normal tissue and well-differentiated carcinoma, production of IL-6 was strongly down-regulated in cultures derived from undifferentiated carcinoma. In contrast, levels of IL-8, TGF-alpha, and TGF-beta produced by neoplastic TFC were similar to those produced by normal cells. Actually, production of TGF-alpha was slightly enhanced in cultures from well-differentiated carcinoma. Immunoassay results were confirmed by reverse transcriptase-PCR analysis. Immunohistochemistry of human thyroid carcinomas (n = 99) and normal thyroid tissue (n = 85) showed that immunoreactive IL-6 was strongly diminished in undifferentiated forms (n = 34) and slightly reduced in well-differentiated carcinoma (n = 65). In agreement with the in vitro results, TGF-alpha expression was significantly increased in neoplastic thyrocytes, as compared to their normal counterpart. The results indicate that, as in the mammary and salivary glands, down-regulation of IL-6 expression may represent a marker of undifferentiated thyroid carcinoma.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9516926

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  11 in total

1.  Interleukins as markers of inflammation in malignant and benign thyroid disease.

Authors:  Xeni Provatopoulou; Despoina Georgiadou; Theodoros N Sergentanis; Eleni Kalogera; John Spyridakis; Antonia Gounaris; George N Zografos
Journal:  Inflamm Res       Date:  2014-05-03       Impact factor: 4.575

2.  Effect of cytostatic proline rich polypeptide-1 on tumor suppressors of inflammation pathway signaling in chondrosarcoma.

Authors:  Karina Galoian; Shihua Luo; Amir Qureshi; Parthik Patel; Rachel Price; Ashlyn S Morse; Gor Chailyan; Silva Abrahamyan; H T Temple
Journal:  Mol Clin Oncol       Date:  2016-09-02

3.  Multiplex analysis of cytokines as biomarkers that differentiate benign and malignant thyroid diseases.

Authors:  Faina Linkov; Robert L Ferris; Zoya Yurkovetsky; Adele Marrangoni; Lyudmila Velikokhatnaya; William Gooding; Brian Nolan; Matthew Winans; Eric R Siegel; Anna Lokshin; Brendan C Stack
Journal:  Proteomics Clin Appl       Date:  2008-10-10       Impact factor: 3.494

4.  Analysis of IL6-protein complexes in chondrosarcoma.

Authors:  Karina Galoian; Shihua Luo; Parthik Patel
Journal:  Biomed Rep       Date:  2017-11-10

5.  Co-expression of interleukin-6 (IL-6) and interleukin-6 receptor (IL-6R) in thyroid nodules is associated with co-expression of CD30 ligand/CD30 receptor.

Authors:  R M Ruggeri; D Villari; A Simone; R Scarfi; M Attard; F Orlandi; G Barresi; F Trimarchi; M Trovato; S Benvenga
Journal:  J Endocrinol Invest       Date:  2002-12       Impact factor: 4.256

6.  Serum hepatocyte growth factor is increased in Hashimoto's thyroiditis whether or not it is associated with nodular goiter as compared with healthy non-goitrous individuals.

Authors:  R M Ruggeri; S Sciacchitano; A Vitale; P Cardelli; M Galletti; E Vitarelli; G Barresi; S Benvenga; F Trimarchi; M Trovato
Journal:  J Endocrinol Invest       Date:  2009-03-25       Impact factor: 4.256

7.  Sprouty1 induces a senescence-associated secretory phenotype by regulating NFκB activity: implications for tumorigenesis.

Authors:  A Macià; M Vaquero; M Gou-Fàbregas; E Castelblanco; J M Valdivielso; C Anerillas; D Mauricio; X Matias-Guiu; J Ribera; M Encinas
Journal:  Cell Death Differ       Date:  2013-11-22       Impact factor: 15.828

8.  Expression of interleukin 6 (IL-6) correlates with oestrogen receptor in human breast carcinoma.

Authors:  G Fontanini; D Campani; M Roncella; D Cecchetti; S Calvo; A Toniolo; F Basolo
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

9.  The -174 G/C gene polymorphism in interleukin-6 is associated with an aggressive breast cancer phenotype.

Authors:  B Iacopetta; F Grieu; D Joseph
Journal:  Br J Cancer       Date:  2004-01-26       Impact factor: 7.640

10.  Significance of Interleukin-6 in Papillary Thyroid Carcinoma.

Authors:  Toral P Kobawala; Trupti I Trivedi; Kinjal K Gajjar; Darshita H Patel; Girish H Patel; Nandita R Ghosh
Journal:  J Thyroid Res       Date:  2016-03-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.